Indrayani Biotech Ltd.

As of March 31, 2026, Indrayani Biotech Ltd. carries a market capitalization of 329.23M, placing it among publicly traded companies globally. Its enterprise value stands at 1.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Indrayani Biotech Ltd. has 45.54M shares outstanding.

As of March 31, 2026, Indrayani Biotech Ltd. trades at a trailing price-to-earnings ratio of 15.34. The price-to-sales ratio is 0.20, and the price-to-book ratio stands at 0.45.

As of March 31, 2026, Indrayani Biotech Ltd. trades at an EV/EBITDA multiple of 13.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.34 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.66B versus a market cap of 329.23M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Indrayani Biotech Ltd. maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.69, indicating elevated leverage, while an interest coverage ratio of 1.03 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Indrayani Biotech Ltd. posted a return on equity (ROE) of 3.06, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.85, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.85M in revenue per employee across its workforce of 936.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.04 indicates how many times Indrayani Biotech Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Indrayani Biotech Ltd. recorded an income tax benefit of -18.33M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 4.42M, leaving 22.24M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Indrayani Biotech Ltd.'s stock has declined approximately 43.35% over the past 52 weeks. The 50-day moving average sits at 8.81, while the 200-day moving average is 9.32.

Over the twelve months ended March 31, 2026, Indrayani Biotech Ltd. generated 1.73B in revenue and converted that into 22.24M in net income, yielding earnings per share of 0.48. EBITDA reached 124.19M, while operating income came in at 71.07M.

As of March 31, 2026, Indrayani Biotech Ltd. holds 245.52M in cash and equivalents against 1.28B in total debt, resulting in a net debt position of 1.24B. Total book value stands at 728.88M, with working capital of 657.39M providing operational flexibility.

Over the twelve months ended March 31, 2026, Indrayani Biotech Ltd. posted a gross margin of 30.47, reflecting its pricing power and cost economics. The operating margin of 4.11 and net profit margin of 1.29 provide insight into operational efficiency.

Indrayani Biotech Ltd.'s most recent stock split took place on September 24, 2010 with a 25:3 split ratio.